Seres Therapeutics Inc
SWB:1S9
Relative Value
The Relative Value of one
1S9
stock under the Base Case scenario is
hidden
EUR.
Compared to the current market price of 6.432 EUR,
Seres Therapeutics Inc
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
1S9 Competitors Multiples
Seres Therapeutics Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Seres Therapeutics Inc
SWB:1S9
|
77m EUR | 215.9 | 14 | -0.3 | -0.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
399.2B USD | 6.7 | 170 | 16.5 | 23.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202.4B USD | 5.5 | 26.2 | 15 | 15 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
188.1B USD | 6.4 | 22.1 | 15 | 15 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121B USD | 10.1 | 30.6 | 23.4 | 24.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.1B USD | 5.7 | 18.3 | 13.8 | 15.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
74.2B AUD | 3.3 | 17.2 | 11.7 | 14.7 | |
| NL |
|
argenx SE
XBRU:ARGX
|
44.2B EUR | 14.2 | 33.5 | 57.5 | 59.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |